Taken together, this evidence indicates different mechanisms on CIC deregulation (inactivating mutations in oligodendroglioma, lung, gastric, hepatocellular carcinomas, and T-ALL; gain-of-functions mutations in sarcomas, including a small percentage of angiosarcomas that were found to carry CIC–LEUTX fusion [49]), but a common upregulation of CIC-target genes. The gene discussed is CIC; the disease is hepatocellular carcinoma.